Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr Spira on Updated MARIPOSA Trial Data in EGFR+ Advanced NSCLC

September 8th 2024

Alexander I. Spira MD, PhD, FACP, FASCO, discusses updated findings from the phase 3 MARIPOSA study in EGFR-mutated locally advanced or metastatic NSCLC.

Global Survey Examines Barriers to Optimal Lung Cancer Biomarker Testing

September 8th 2024

Global surveys from 2018 and 2024 demonstrated barriers to optimizing biomarker testing for patients with early- or late-stage lung cancer.

Ifinatamab Deruxtecan Shows Improved Clinical Activity at Higher Dose in ES-SCLC

September 7th 2024

A 12-mg/kg dose of ifinatamab deruxtecan improved efficacy compared with an 8-mg/kg dose in heavily pretreated patients with extensive-stage small cell lung cancer.

Dr Patel on the FDA Approval of Durvalumab Plus Chemotherapy for NSCLC

September 6th 2024

Sandip P. Patel, MD, discusses the FDA approval of perioperative durvalumab plus chemotherapy for patients with non–small cell lung cancer.

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

September 5th 2024

Dr Florez discusses ways that she helps patients with lung cancer understand the importance of biomarker testing.

Dr Cooper on Considerations to Help Guide ADC Use in Second-Line NSCLC

September 5th 2024

Alissa J. Cooper, MD, discusses insights from the TROPION-Lung01 trial that may help guide antibody-drug conjugate use in second-line NSCLC.

Novel Targets, Classes of Agents Could Refine Checkpoint Inhibition in NSCLC

September 4th 2024

Solange Peters, MD, PhD, discusses ways to refine checkpoint inhibition in the treatment of non–small cell lung cancer.

Dr Sabari on the FDA Approval of Amivantamab/Lazertinib in EGFR+ Advanced NSCLC

September 4th 2024

Joshua K. Sabari, MD, discusses FDA approval of first-line amivantamab plus lazertinib for locally advanced or metastatic EGFR-mutated non–small cell lung cancer.

OncLive’s August Roundup of Key FDA Approvals in Oncology

September 4th 2024

Here is your snapshot of all therapeutic options that the FDA approved in August 2024 and their clinical implications.

The OncFive: Top Oncology Articles for the Week of 8/25

August 31st 2024

Mirdametinib NDA gets priority review in NF1-associated plexiform neurofibromas, experts explore social media's evolving role in cancer care, and more.

Encorafenib/Binimetinib Combo Approved in Europe for BRAF V600E+ NSCLC

August 30th 2024

Encorafenib plus binimetinib has won approval from the European Commission for use in patients with BRAF V600E-mutated, advanced non–small lung cancer.

Revisit Every OncLive On Air Episode From August 2024

August 30th 2024

In case you missed any, below is a recap of every OncLive On Air episode that aired in August 2024.

Merck to Discontinue KEYNOTE-867 and KEYNOTE-630 Trials of Pembrolizumab in NSCLC, CSCC

August 29th 2024

The phase 3 KEYNOTE-867 and KEYNOTE-630 trials evaluating pembrolizumab in NSCLC and CSCC, respectively, have been discontinued by Merck.

Dr Singhi on the Potential Benefit of the ADRIATIC Study Findings in LS-SCLC

August 29th 2024

Eric Kumar Singhi, MD, discusses unmet needs in the management of small cell lung cancer, highlighting how the ADRIATIC study addressed these needs.

Nailing it Down: What Will AI’s Role Be in Cancer Care?

August 28th 2024

Krishnansu S. Tewari, MD, details the current and possible future applications of AI in cancer care as well as the limitations of the technology.

Amivantamab Plus Chemotherapy Wins EU Approval for Pretreated EGFR+ Advanced NSCLC

August 27th 2024

Amivantamab plus chemotherapy has received European approval for EGFR-mutant non–small cell lung cancer that progressed on an EGFR TKI.

Dr Singhi on Areas of Interest in Metastatic Lung Cancer Research

August 26th 2024

Eric Kumar Singhi, MD, discusses potential areas of research interest in the treatment of patients with metastatic lung cancer.

The OncFive: Top Oncology Articles for the Week of 8/18

August 24th 2024

A frontline doublet receives FDA approval in EGFR+ NSCLC, a CRL is issued to linvoseltamab in multiple myeloma, and more this week from OncLive.

Tepotinib Plus Osimertinib Demonstrates Activity in EGFR+ NSCLC

August 23rd 2024

Data from the INSIGHT 2 study showed that tepotinib plus osimertinib elicited responses in patients with EGFR-mutated non–small cell lung cancer.

Fulzerasib Approved in China for KRAS G12C–Mutant Advanced NSCLC

August 22nd 2024

China’s National Medical Products Administration has approved fulzerasib for the treatment of adult patients with advanced KRAS G12C–mutant NSCLC.